Correlation Between Nuvectis Pharma and Cadrenal Therapeutics,

Can any of the company-specific risk be diversified away by investing in both Nuvectis Pharma and Cadrenal Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Nuvectis Pharma and Cadrenal Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Nuvectis Pharma and Cadrenal Therapeutics, Common, you can compare the effects of market volatilities on Nuvectis Pharma and Cadrenal Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Nuvectis Pharma with a short position of Cadrenal Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Nuvectis Pharma and Cadrenal Therapeutics,.

Diversification Opportunities for Nuvectis Pharma and Cadrenal Therapeutics,

0.35

Correlation Coefficient

Nuvectis Pharma  Cadrenal Therapeutics,

Weak diversification

The 3 months correlation between Nuvectis and Cadrenal is 0.35. Overlapping area represents the amount of risk that can be diversified away by holding Nuvectis Pharma and Cadrenal Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cadrenal Therapeutics, and Nuvectis Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Nuvectis Pharma are associated (or correlated) with Cadrenal Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cadrenal Therapeutics, has no effect on the direction of Nuvectis Pharma i.e., Nuvectis Pharma and Cadrenal Therapeutics, go up and down completely randomly.

Pair Corralation between Nuvectis Pharma and Cadrenal Therapeutics,

Given the investment horizon of 90 days Nuvectis Pharma is expected to under-perform the Cadrenal Therapeutics,. In addition to that, Nuvectis Pharma is 1.03 times more volatile than Cadrenal Therapeutics, Common. It trades about 0.0 of its total potential returns per unit of risk. Cadrenal Therapeutics, Common is currently generating about 0.15 per unit of volatility. If you would invest  795.00  in Cadrenal Therapeutics, Common on August 31, 2024 and sell it today you would earn a total of  620.00  from holding Cadrenal Therapeutics, Common or generate 77.99% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	98.44%
Values	Daily Returns

Nuvectis Pharma  vs.  Cadrenal Therapeutics, Common

Nuvectis Pharma

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Nuvectis Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable fundamental indicators, Nuvectis Pharma is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors.

Cadrenal Therapeutics,

Risk-Adjusted Performance

11 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Cadrenal Therapeutics, Common are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of rather unsteady forward-looking signals, Cadrenal Therapeutics, exhibited solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Nuvectis Pharma and Cadrenal Therapeutics,

The main advantage of trading using opposite Nuvectis Pharma and Cadrenal Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Nuvectis Pharma position performs unexpectedly, Cadrenal Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cadrenal Therapeutics, will offset losses from the drop in Cadrenal Therapeutics,'s long position.

The idea behind Nuvectis Pharma and Cadrenal Therapeutics, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.